Bionano genomics news.

Submissions focused on a variety of applications including genetic disease, cancer, reproductive health, cell and gene therapy, and plant and animal research. SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the 2023 winners of its Innovator Research Grant program, including grand prize winner Dr ...SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2023. Business Updates Since the End ...12 Okt 2021 ... Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal. While both companies provide genomics ...SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, a...

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform ...Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. GlobeNewswire.

Track Bionano Genomics Inc (BNGO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Good afternoon, everyone. Welcome to the Bionano Genomics first quarter 2023 financial results conference call. Leading the call today is Dr. Erik Holmlin, CEO of Bionano; joined by Chris Stewart ...

Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing Jan 19 Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022Bionano Genomics (BNGO-8.48%) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Here's ...A big change in the C-suite was behind the steep fall in Bionano Genomics ' ( BNGO -12.27%) share price on Monday. Following the biotech's announcement that its CFO is stepping down, investors ...Jun 30, 2023 · Bionano participated at key cytogenetic conferences, including the European Hematology Association (EHA) 2023 Congress, the European Human Genetics (ESHG) 2023 Conference, the European Association for Cancer Research (EACR) 2023 Congress and the International Society for Stem Cell Research (ISSCR) Annual Meeting 2023. OGM was featured in 37 ...

BNGO | Complete Bionano Genomics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Bionano Genomics (BNGO 4.40%) Q2 2023 Earnings Call Aug 09, 2023, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good day, and ...

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2023. Business Updates Since the End ...14 Okt 2021 ... 22, 2021. Source: Bionano Genomics. Related Content: Bio/Pharma News ...The National Human Genome Research Institute says that strawberries have seven unique chromosomes. However, through human breeding, strawberries are capable of having many different chromosomal combinations by variety.SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural ...Bionano Genomics. May 9, 2023 at 4:01 PM · 17 min read. Bionano Genomics. Q1 2023 revenue was $7.4 million, which represents a 30% increase over Q1 2022. Installed base of 259 Saphyr® systems ...Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025 and warrants Preliminary Q3 revenue expected to be between $9.1 and $9.3 million , which would

15 Jan 2021 ... That is the question for those investing in Bionano Genomics (NASDAQ: BNGO). ... The news comes on top of advances in coronavirus and in the ...Headline. After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO) finance.yahoo.com - November 17 at 2:20 PM. Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Ascendis Pharma (ASND) markets.businessinsider.com - November 16 at 11:51 PM.7 Agu 2023 ... Bionano Genomics (NASDAQ: BNGO) stock will jump 1000% at the open this morning. BNGO stock rising 10x is not, sadly, to make up for the ...Oct '23 Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan Oct '23 Bionano Announces Pricing of $80.0 Million Registered Offering and Concurrent Private Placement of Senior Secured Convertible Notes and Warrants Current page 1 2 Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform ...

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, March 9 th, 2023 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2022 and to highlight recent corporate progress.. Conference Call & …In 2022, BNGO's revenue was $27.80 million, an increase of 54.62% compared to the previous year's $17.98 million. Losses were -$132.60 million, 83.1% more than in 2021. According to 4 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is $46.67, which is an increase of 2,853.80% from the latest …

30 Des 2020 ... Bionano Genomics (BNGO) stock is on the move Wednesday with heavy trading following an update from the Nasdaq about its listing status.SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for solid tumor and hematological malignancy cancer research, including scientific …Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. GlobeNewswire.SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.BNGO | Complete Bionano Genomics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Jun 14, 2023 · Bionano Announces Results from its Annual Meeting of Stockholders. SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today. The final voting results will be available in a current report on Form 8-K, which ... Os últimos tweets de @bionanogenomicsBionano Reports First Quarter 2023 Results and Highlights Recent Business Progress. Q1 2023 revenue was $7.4 million, which represents a 30% increase over Q1 2022. Installed base of 259 Saphyr ...Pharma, BioPharma. Bionano frames $90M BioDiscovery buy as way to expand genomics analysis Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal.

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, a...

Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 [email protected] Investor Relations: David Holmes Gilmartin Group +1 (858) 888-7625 [email protected]

Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025 and warrants Preliminary Q3 revenue expected to be between $9.1 and $9.3 million , which wouldA-smart is Bionano’s second Chinese OEM partner to obtain approval from NMPA for the Company’s optical genome mapping (OGM) solutions. NMPA issued two approvals to A-smart: one for Bionano’s G2 direct label and stain (DLS) DNA labeling kit and one for Bionano’s G2 SP bone marrow aspirate (BMA) DNA isolation kit.SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory …Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. GlobeNewswire.Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.11 per share a year ago.NEW YORK – Bionano Genomics this week executed a new round of layoffs, GenomeWeb has learned. According to information obtained by GenomeWeb from former employees who wished to remain anonymous, the workforce reduction appears to impact around 60 employees, although company executives declined to comment.Bionano Genomics Expects $80 Million in Gross Proceeds From Registered Offering, Private Placement. Oct. 11. MT. Bionano Genomics, Inc. Revises Revenue Guidance for the Third Quarter Ended September 30, 2023. Oct. 11. CI. Bionano Genomics, Inc. announced that it expects to receive $35 million in funding. Oct. 10.Bionano Genomics has an overall rating of 3.2 out of 5, based on over 48 reviews left anonymously by employees. 55% of employees would recommend working …Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to …Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025 and warrants Preliminary Q3 revenue expected to be between $9.1 and $9.3 million , which wouldFor the last reported quarter, it was expected that Bionano Genomics, Inc. Would post a loss of $0.90 per share when it actually produced a loss of $1.24, delivering a surprise of -37.78%.Instagram:https://instagram. best mortgage lenders for low incomemutual funds taxesslmuco etf stock 24 Agu 2023 ... Join us for an installment of our Bionano In Motion webinar series as our speakers delve into immunotherapies and the emerging role of ... best investments for seniorstax loss harvesting vanguard Following the downgrade, the current consensus from Bionano Genomics' five analysts is for revenues of US$40m in 2023 which - if met - would reflect a huge 53% increase on its sales over the past ...Jan 12, 2023 · About Bionano Genomics, Inc. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. best gold mutual funds 2023 BNGO | Complete Bionano Genomics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Track Bionano Genomics Inc (BNGO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors